CTI Biopharma reported $1.22M in Cost of Sales for its fiscal quarter ending in March of 2023.


Cost Of Sales Change Date
Baxter International USD 1.82B 55M Jun/2025
Bristol-Myers Squibb USD 3.37B 339M Jun/2025
Eli Lilly USD 2.45B 223.6M Jun/2025
Geron 1.19M 16K Jun/2025
Incyte USD 78.77M 10.96M Jun/2025
Novartis USD 3.32B 95M Jun/2025
Novartis USD 3.32B 5M Jun/2025